We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 126.88 | 0 | 01:00:00 |
By Colin Kellaher
Merck & Co. on Tuesday reported positive results for its V114 investigational 15-valent pneumococcal conjugate vaccine in two additional phase 3 studies.
The Kenilworth, N.J., drug maker said V114 met its primary immunogenicity objectives and elicited a strong immune response for all 15 serotypes included in the vaccine, including 22F and 33F, the two serotypes targeted by V114 but not by the currently available 13-valent pneumococcal conjugate vaccine.
Merck said V114 was generally well tolerated in both studies, with a safety profile consistent with that observed in previously reported studies.
Merck in September said a pair of phase 3 studies evaluating V114 had met their primary immunogenicity objectives.
The company said its plans for global regulatory licensure applications, beginning with the U.S. Food and Drug Administration before the end of the year, remain on track.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 20, 2020 07:23 ET (11:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions